TEL AVIV - SciSparc Ltd. (NASDAQ:SPRC), a pharmaceutical company specializing in central nervous system therapies, announced today its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND) (FSE:CWY) has led to the filing of three international patent applications.
These applications relate to novel compositions involving MDMA, ibogaine, and ketamine, each paired with palmitoylethanolamide (PEA), a key ingredient in SciSparc's CannAmide™.
The patent filings under the Patent Cooperation Treaty (PCT) are an expansion of the provisional patent applications previously submitted to the United States Patent and Trademark Office (USPTO).
In total, Clearmind has filed eight USPTO applications for various compounds, including three that combine PEA with Clearmind’s 5-methoxy-2-aminoindane, targeting treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. Additionally, seven applications have been filed under the PCT.
SciSparc's current drug development programs focus on cannabinoid-based pharmaceuticals, including SCI-110 for Tourette Syndrome and Alzheimer's disease, SCI-160 for pain treatment, and SCI-210 for Autism Spectrum Disorder (ASD) and status epilepticus. The company also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon.com (NASDAQ:AMZN).
The press release includes forward-looking statements under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. SciSparc has made these statements based on current expectations, which are subject to risks and uncertainties. The company's actual results could materially differ from those anticipated in these statements. These risks are detailed in SciSparc's Annual Report on Form 20-F and other SEC filings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.